News Daily News Many ESC Guideline Recommendations Out of Reach in Poorer Regions Michael O'Riordan November 29, 2022
News Daily News Exposure to Lead Linked to Risk of CVD Mortality: Strong Heart Study Michael O'Riordan November 18, 2022
News Conference News AHA 2022 Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION Michael O'Riordan November 09, 2022
News Conference News AHA 2022 First-line Ablation Reduces AF Progression, Boosts Quality of Life Todd Neale November 07, 2022
News Conference News AHA 2022 STRONG-HF: Rapid Uptitration of GDMT After Acute HF Pays Dividends Todd Neale November 07, 2022
News Conference News AHA 2022 ISCHEMIA-EXTEND: So Far, Deaths Match for Invasive and Conservative Arms in Stable CAD Shelley Wood November 06, 2022
News Conference News AHA 2022 EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD Todd Neale November 06, 2022
News Conference News AHA 2022 IRONMAN Misses but Lends Support to IV Iron Repletion in HF Shelley Wood November 05, 2022
News Conference News AHA 2022 In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE Todd Neale November 05, 2022
News Conference News AHA 2022 TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF Todd Neale November 05, 2022
News Conference News AHA 2022 Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions Yael L. Maxwell November 01, 2022
Presentation Cardiovascular Interventions 2022 Do All Patients with New Onset HF Need Assessment for CAD? Presenter: J. Thomas Heywood October 28, 2022
News Daily News SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal BP Care Resumes Michael O'Riordan October 18, 2022
News Daily News STRONG-HF: Fast Optimal GDMT Cuts Deaths, Hospitalizations in Acute HF Shelley Wood October 17, 2022
News Daily News COVID Drug Paxlovid Interacts With Widely Used CV Meds: Review Todd Neale October 12, 2022
News Conference News HFSA 2022 New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented Todd Neale October 07, 2022
News Conference News HFSA 2022 REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status L.A. McKeown October 07, 2022
News Daily News Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use L.A. McKeown October 05, 2022
News Conference News HFSA 2022 GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions Michael O'Riordan October 04, 2022